18th February 2021 • comment

Pfizer and BioNTech have announced that their vaccine candidate against COVID-19 achieved success in the first interim analysis from the phase 3 COVID-19 vaccine trial.

10th November 2020 • comment
26th October 2020 • comment
30th September 2020 • comment
17th July 2020 • comment
1st July 2020 • comment
25th June 2020 • comment

Vaccine Efficacy Assessment for COVID-19

by Edde Loeliger and Bob Small
7th May 2020 • comment

The SARS-CoV-2 pandemic presents an unprecedented challenge to global health with enormous health system, social and economic disruption and large numbers of deaths already experienced in many countries. Epidemiologic features confirm that ongoing spread to less affected areas is now a certainty.

20th March 2020 • comment

To maximize the value of vaccine safety data in clinical trials given their relatively limited sample size, it is essential to standardize their collection, presentation and analysis when possible.Given serious adverse events following immunization (AEFIs) are fortuitously rare, this need for globally accepted standard case definitions that allow for valid comparisons extend to individual case reports, surveillance systems, and retrospective epidemiologic studies.

5th March 2020 • comment